NASDAQ : SRPT
Sarepta Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 18.625 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.97B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.97B |
| Enterprise Value | 2.24B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 105.63M |
| Shares Outstanding | 105.63M |
| Shares Change (YoY) | +7.36% |
| Shares Change (QoQ) | -13.52% |
| Owned by Insiders (%) | 4.78% |
| Owned by Institutions (%) | 102.55% |
| Float | 100.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 82.46 |
| PS Ratio | 1.00 |
| Forward PS | 1.40 |
| PB Ratio | 1.29 |
| P/TBV Ratio | 1.31 |
| P/FCF Ratio | 24.03 |
| P/OCF Ratio | 17.72 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 1.13 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 27.38 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.42 |
| Quick Ratio | 2.44 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | 7.07 |
| Debt / FCF | 12.98 |
| Interest Coverage | -0.87 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -9.48% |
| Return on Assets (ROA) | -1.13% |
| Return on Invested Capital (ROIC) | -3.36% |
| Return on Capital Employed (ROCE) | -2.32% |
| Weighted Average Cost of Capital (WACC) | 5.97% |
| Revenue Per Employee | $2.36M |
| Profits Per Employee | -$163,743 |
| Employee Count | 835 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.68 |
Taxes
| Measure | Value |
|---|
| Income Tax | 5.81M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.38 |
| 52-Week Price Change | -20.60% |
| 50-Day Moving Average | 19.24 |
| 200-Day Moving Average | 18.72 |
| Relative Strength Index (RSI) | 51.21 |
| Average Volume (20 Days) | 2,778,366 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 22.33M |
| Short Previous Month | 22.78M |
| Short % of Shares Out | 21.14% |
| Short % of Float | 22.21% |
| Short Ratio (days to cover) | 7.84 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.97B |
| Gross Profit | 377.26M |
| Operating Income | -62.24M |
| Pretax Income | -130.92M |
| Net Income | -136.73M |
| EBITDA | -17.53M |
| EBIT | -62.24M |
| Loss Per Share | -$1.32 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 788.49M |
| Total Debt | 1.06B |
| Net Cash | -273.92M |
| Net Cash Per Share | -$2.59 |
| Equity (Book Value) | 1.53B |
| Book Value Per Share | 14.46 |
| Working Capital | 1.72B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 111.01M |
| Capital Expenditures | -29.16M |
| Depreciation & Amortization | 44.71M |
| Net Borrowing | -159.07M |
| Free Cash Flow | 81.85M |
| FCF Per Share | $0.77 |
Margins
| Measure | Value |
|---|
| Gross Margin | 19.11% |
| Operating Margin | -3.15% |
| Pretax Margin | -6.63% |
| Profit Margin | -6.93% |
| EBITDA Margin | -0.89% |
| EBIT Margin | -3.15% |
| FCF Margin | 4.15% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.36% |
| Shareholder Yield | -7.36% |
| Earnings Yield | -7.07% |
| FCF Yield | 4.16% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $21.64 |
| Price Target Difference | 16.22% |
| Analyst Consensus | Hold |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | -16.16% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 12, 2012 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -0.07 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |